Poor outcome of two children with relapsed state stage IV alveolar rhabdomyosarcoma after allogeneic stem cell transplantation

Pediatric Hematology and Oncology

Volumn 22, Issue 8, 2005, Pages 699-703

  Doelken, Regina ^a   Weigel, Steffen ^a   Schueler, Frank ^a   Doelken, Gottfried ^a   Beck, James F ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Allogeneic stem cell transplantation; Alveolar rhabdomyosarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DACTINOMYCIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; IDARUBICIN; IFOSFAMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; THIOTEPA; TREOSULFAN; TROFOSFAMIDE; VINCRISTINE;

ADOLESCENT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; DEATH; DRUG MEGADOSE; ECHOGRAPHY; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HAND AMPUTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; METASTASIS; MYELOABLATIVE CONDITIONING; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; RHABDOMYOSARCOMA; SCHOOL CHILD; TREATMENT OUTCOME; TUMOR BIOPSY;

ADOLESCENT; CHILD; DISEASE PROGRESSION; FATAL OUTCOME; GERMANY; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; NEOPLASM STAGING; RECURRENCE; RHABDOMYOSARCOMA, ALVEOLAR; TREATMENT OUTCOME;

EID: 27644482033     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.1080/08880010500278806     Document Type: Article

References (21)

1. Grist W, Gehan EA, Ragab AH, et al. The Third Intergroiip Rhabdomyosarcoma Study. J Clin Oncol. 1995;13:610-630.
2. Miller DV, Coffin CM, Zhou H. Rhabdomyosarcoma arising in the hand or foot: a clinicopathologic analysis. Pediatr Dev Pathol 2004;7:361-339.
3. Seeger RC, Reynolds CP. Treatment of high-risk solid tumors of childhood with intensive therapy and autologous bone marrow transplantation. Pediatr Clin North Am. 1991;38:393-424.
4. Emminger W, Emminger-Schmidmeier W, Hawliczek R, Peters C, Hocker P, Gadner H. High-dose melphalan, etoposide +/- carboplatin (MEC) combined with 12-gray fractionated total-body irradiation in children with generalized solid tumors. Pediatr Hematol Oncol. 1991;8:13-22.
5. Shuster JJ, Cantor AB, McWilliams N, et al. The prognostic significance of autologous bone marrow transplant in advanced neuroblastoma. J Clin Oncol. 1991;9:1045-1049.
6. Pinkerton CR, Groot-Loonen J, Barrett A, et al. Rapid VAC high dose melphalan regimen, a novel chemotherapy approach in childhood soft tissue sarcomas. Br J Cancer. 1991;64:381-385.
7. Pinkerton R. [Massive chemotherapy followed by bone marrow graft in pediatric oncology: arguments against]. Bull Cancer. 1995;82:42-45.
8. Burdach S, Jurgens H, Peters C, et al. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. J Clin Oncol. 1993;11:1482-1488.
9. Ladenstein R, Hartmann O, Pinkerton CR. The role of megatherapy with autologous bone marrow rescue in solid tumours of childhood. Ann Oncol. 1993;4(Suppl 1):45-58.
10. Burdach S, van Kaick B, Laws HJ, et al. Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors: an update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Dusseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. Ann Oncol. 2000;11:1451-1462.
11. Bader P, Kreyenberg H, Hoelle W, et al. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy? J Clin Oncol. 2004;22:1696-1705.
12. Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood. 1991;77:649-653.
13. Mandingers CM, Meijerink JP, Raemaekers JM, Schattenberg AV, Mensink EJ. Graft-versus-lymphoma effect of donor leucocyte infusion shown by real-time quantitative PCR analysis of t(14;18). Lancet. 1998;352:1522-1523.
14. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma alter non-myeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000;343:750-758.
15. Koscielniak E, Klingebiel TH, Peters C, et al. Do patients with metastatic and recurrent rhabdomyosarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/ Austrian Pediatric Bone Marrow Transplantation Group. Bone Marrow Transplant. 1997;19:227-231.
16. Maurer HM, Beltangady M, Gehan EA, et al. The Intergroup Rhabdomyosarcoma Study, I: a final report. Cancer. 1988;61:209-220.
17. Koscielniak E, Jurgens H, Winkler K, et al. Treatment of soft tissue sarcoma in childhood and adolescence: a report of the German Cooperative Soft Tissue Sarcoma Study. Cancer. 1992;70:2557-2567.
18. Flamant F, Hill C. The improvement in survival associated with combined chemotherapy in childhood rhabdomyosarcoma: a historical comparison of 345 patients in the same center. Cancer. 1984;53:2417-2421.
19. Carli M, Colombatti R, Oberlin O, et al. High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma. J Clin Oncol. 1999;17:2796-2803.
20. Chan KW, Rogers PC, Fryer CJ. Breast metastases after bone marrow transplantation for rhabdomyosarcoma. Bone Marrow Transplant. 1991;7:171-172.
21. Bader P, Hancock J, Kreyenberg H, et al. Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL. leukemia. 2002;16:1668-1672.